Genomic resistant determinants of multidrug-resistant Campylobacter spp. isolates in Peru
Nombre:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Autor
Schiaffino, FrancescaParker, Craig T.
Paredes Olortegui, Maribel
Pascoe, Ben
Manzanares Villanueva, Katia
Garcia Bardales, Paul F.
Mourkas, Evangelos
Huynh, Steven
Peñataro Yori, Pablo
Romaina Cachique, Lucero
Gray, Hannah K.
Salvatierra, Guillermo
Silva Delgado, Hermann
Sheppard, Samuel K.
Cooper, Kerry K.
Kosek, Margaret N.
Fecha de publicación
2024-03-01
Metadatos
Mostrar el registro completo del ítemEditorial
Elsevier LtdJournal
Journal of Global Antimicrobial ResistanceDOI
10.1016/j.jgar.2024.01.009Resumen
Objectives: Antimicrobial resistant (AMR) Campylobacter is a global health threat; however, there is limited information on genomic determinants of resistance in low- and middle-income countries. We evaluated genomic determinants of AMR using a collection of whole genome sequenced Campylobacter jejuni and C. coli isolates from Iquitos, Peru. Methods: Campylobacter isolates from two paediatric cohort studies enriched with isolates that demonstrated resistance to ciprofloxacin and azithromycin were sequenced and mined for AMR determinants. Results: The gyrA mutation leading to the Thr86Ile amino acid change was the only gyrA mutation associated with fluoroquinolone resistance identified. The A2075G mutation in 23S rRNA was present, but three other 23S rRNA mutations previously associated with macrolide resistance were not identified. A resistant-enhancing variant of the cmeABC efflux pump genotype (RE-cmeABC) was identified in 36.1% (35/97) of C. jejuni genomes and 17.9% (12/67) of C. coli genomes. Mutations identified in the CmeR-binding site, an inverted repeat sequence in the cmeABC promoter region that increases expression of the operon, were identified in 24/97 C. jejuni and 14/67 C. coli genomes. The presence of these variants, in addition to RE-cmeABC, was noted in 18 of the 24 C. jejuni and 9 of the 14 C. coli genomes. Conclusions: Both RE-cmeABC and mutations in the CmeR-binding site were strongly associated with the MDR phenotype in C. jejuni and C. coli. This is the first report of RE-cmeABC in Peru and suggests it is a major driver of resistance to the principal therapies used to treat human campylobacteriosis in this setting.Tipo
info:eu-repo/semantics/articleDerechos
info:eu-repo/semantics/openAccessAttribution-NonCommercial-NoDerivatives 4.0 International
Idioma
engISSN
22137165EISSN
22137173Patrocinadores
National Institutes of Healthae974a485f413a2113503eed53cd6c53
10.1016/j.jgar.2024.01.009
Scopus Count
Colecciones
El ítem tiene asociados los siguientes ficheros de licencia:
- Creative Commons
Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/openAccess